The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Levonorgestrel IUDs changes failed insertion compared with copper IUDs (very low certainty).
It is very uncertain whether summary of findings table ‐ Levonorgestrel IUDs changes rates of expulsion compared with copper IUDs (very low certainty).
It is very uncertain whether summary of findings table ‐ Levonorgestrel IUDs changes rates of removal compared with copper IUDs (very low certainty).
It is very uncertain whether summary of findings table ‐ Levonorgestrel IUDs changes patient satisfaction compared with copper IUDs (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
The review found no eligible studies for this question.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
The review found no eligible studies for this question.
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).